Friday, July 10, 2026
🇺🇸 FDA

pharma · Mantle Cell Lymphoma · Colon cancer

Telethon Foundation

Fondazione Telethon ETS

Telethon Foundation trial registry — 162 ClinicalTrials.gov studies with program phase, status, and indication context.

Website Investor relations
roma, IT HQ
1990 Founded
343 Employees
EMA registrant Type
Company details
Status
Public
HQ
roma, IT
Founded
1990
Employees
343
Programs
162
Drugs
285
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Trials

Telethon Foundation clinical trials

Registry index of 162 ClinicalTrials.gov studies linked to Telethon Foundation programs — each row shows trial ID, program name, phase, status, and indication.

Telethon Foundation trial registry — 162 ClinicalTrials.gov studies with program phase, status, and indication context.

Recent trial activity

8 updates

Latest clinical program signals indexed for Telethon Foundation.

  1. CABOMETYX for bladder carcinoma of urothelial… — Phase 2

    Clinical update

  2. REPRINT — Phase 2

    Clinical update

  3. PreSave — Phase 2

    Clinical update

  4. MITO 35a — Phase 2

    Clinical update

  5. GIM35-RIBOSIL — Phase 2

    Clinical update

  6. DIPG — Phase 2

    Clinical update

  7. CML1624 — Phase 2

    Clinical update

  8. CML1415 - Sustrenim — Approved

    Clinical update

Trial registry

162 studies
  26. 2023-510516-39-00

    ALL2418

    Phase 2 active small_molecule

    Acute B-cell Lymphoblastic Leukemia with minimal residual positive disease prior to haematopoietic stem cell transplantation in adult patients

    CTIS ↗
  50. 2024-513592-41-00

    OM 85OLDER

    Approved active small_molecule

    Elderly patients with a positive history of at least two respiratory system infections in the year preceding enrollment and residents for at least 6 months in a Healthcare Residence.

    CTIS ↗
  52. 2024-513660-26-00

    SMILE

    Phase 2 active small_molecule

    Subjects at high risk of inflammatory state and mortality from lung cancer, other cancers and all causes

    CTIS ↗
  61. 2024-515204-39-00

    CEMIPLIMAB

    Phase 2 active small_molecule

    surgically resectable, high risk stage III/IV (M0) Cutaneaous Squamous Cell Carcinoma, Cutaneaous Squamous Cell Carcinoma

    CTIS ↗
  90. 2024-517378-22-00

    CNAO 44 2021C

    Phase 2 active small_molecule

    Unresectable or metastatic melanoma, Locally advanced or metastatic urothelial carcinoma, Locally advanced or metastatic non-small cell lung cancer (NSCLC), Untreated recurrent/metastatic head & neck sqamous cell carcinoma (HNSCC)

    CTIS ↗
  139. 2024-519568-42-00

    CAPTURE

    Phase 2 active small_molecule

    Patients with advanced oncologic disease receiving active treatment with WHO level II or III opioids and adjuvants therapies

    CTIS ↗
  149. 2025-520762-22-00

    ELACESTRANT

    Phase 2 active small_molecule

    Patients with HR-positive, HER2-negative, non-metastatic node positive BC eligible for neoadjuvant treatment (clinical stage II-III)

    CTIS ↗

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.